Northeast Health Services offers SPRAVATO®, FDA-approved nasal spray for treatment-resistant depression, providing fast, effective symptom relief.

WOBURN, MA, UNITED STATES, June 11, 2025 /EINPresswire.com/ -- Northeast Health Services is thrilled to announce that its Woburn clinic is now offering Spravato^® as part of its commitment to providing innovative and effective treatment options for mental health.

Northeast Health Services is proud to offer Spravato^®, the first nasal spray approved by the FDA for treating adults with treatment resistant depression. Spravato^®, also known as esketamine, is a fast-acting treatment, with clients often feeling relief from their depression symptoms within hours. It works by rapidly altering brain chemistry to provide relief from symptoms such as sadness, hopelessness, and loss of interest in activities. Historically Spravato^® has been used in conjunction with an oral antidepressant; however, new FDA approval allows use of Spravato^® without a concurrent oral antidepressant. Read more about this development here: https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression. Spravato^® is administered at Northeast Health Services' approved clinics under the close supervision of a healthcare professional and is now more accessible than ever.

In a short-term study, patients treated with Spravato^® combined with an oral antidepressant experienced a faster and...